MOTESANIB (FREE BASE)

Background Information:

An orally bioavailable inhibitor of a multiple-receptor tyrosine
kinase inhibitor with potential antineoplastic activity. Motesanib
selectively targets VEGF, PDGF, kit, and Ret receptors, thereby
inhibiting angiogenesis and cellular proliferation.

Reference:

1. Polverino, A., et al., AMG 706, an oral, multikinase inhibitor
that selectively targets vascular endothelial growth factor,
platelet-derived growth factor, and kit receptors, potently inhibits
angiogenesis and induces regression in tumor xenografts, Cancer
Research, 2006, 66 (17), 8715-8721.
2. Sherman, S.I, et al, Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer, N Engl J Med. 2008, 359:31-42.

APIM050203: MOTESANIB (FREE BASE)

CAS No.: 453562-69-1.
Molecular Formula: C₂₂H₂₃N₅O.
Molecular Weight: 373.45.
Purity: > 99% (HPLC).
QC: LC/MS, ¹HNMR.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.